Advertisement

Topics

Argus Biosciences LLC Company Profile

07:43 EDT 20th June 2018 | BioPortfolio

Argus Biosciences was founded in 2003 by Dr. David Whyte.Dr. Whyte received his Ph.D. in Molecular Biology from the University of California, San Francisco, and has a Bachelors of Science degree in Chemistry from the University of Michigan, Ann Arbor.After receiving his doctorate, Dr. Whyte worked as a Principal Scientist at the Schering Plough Research Institute in Kenilworth, New Jersey, and as Director of Molecular Technologies at SUGEN, South San Francisco, California.
Our focus is personalized DNA sequence analysis.In addition to offering sequence analysis of medically significant genes, we have recently added a suite of products in the area of molecular genealogy.

Location

2033 Ralston Ave, #84
Belmont
California
94002
United States of America

Contact

Phone: 650-954-1055
Email: info@argusbio.com


News Articles [674 Associated News Articles listed on BioPortfolio]

Second Sight enters Singapore market with Argus II implantation

The Argus II retinal prosthesis system has been implanted in the first patient in Singapore, according to a press release from Second Sight Medical Products.The surgery, performed at the Singapore Nat...

Cardinal Health (CAH) Stock Rating Upgraded by Argus

The firm presently has a $85.00 target price on the stock. Argus' target price indicates a potential upside of 38.71% from the company's current price.

Celgene-Aktie: Furcht vor größerer Volatilität!

New York (www.aktiencheck.de) - Celgene-Aktienanalyse von Analyst David Toung von Argus Research: David Toung, Aktienanalyst vom Investmenthaus Argus Research, empfiehlt im Rahmen einer Aktienanaly...

Intel-Aktie: Schlag für die Reputation! - Aktienanalyse

New York - Intel-Aktienanalyse von Analyst Jim Kelleher von Argus Research: Jim Kelleher, Analyst beim Investmenthaus Argus Research, empfiehlt die Aktien des Chipproduzenten Intel Corp. (ISIN: US4...

Biogen-Aktie: Ausblick verdunkelt sich!

New York - Biogen-Aktienanalyse von Analyst David Toung von Argus Research: Laut einer Aktienanalyse empfiehlt der Analyst David Toung von Argus Research die Aktien des US-Biotechkonzerns Biogen In...

ASC Biosciences, Inc. announces ad dates for first television commercial

About ASC Biosciences, Inc.ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company with a proprietary adult stem cell platform capable Read more...

SOLID BIOSCIENCES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Solid Biosciences Inc. to Contact The Firm

NEW YORK, NY / ACCESSWIRE / April 9, 2018 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Solid Biosciences Inc. ("Solid Biosciences" or th...

Kuros Biosciences Ltd.: Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus

Schlieren (Zürich), Schweiz, 8. Januar 2018 Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus Kuros Biosciences AG (SIX: KURN) gibt die Ausdehnung des exklusiven Lizenzabkommens mit Checkm...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [79 Associated PubMed Articles listed on BioPortfolio]

Positive Visual Phenomena Following Implantation of the Argus II Retinal Prosthesis.

A 62-year-old female who was legally blind secondary to retinitis pigmentosa (RP) developed new positive visual phenomena (PVP) ("visual storms") following implantation of the Argus II Retinal Prosthe...

Multimodal Imaging Including Optical Coherence Tomography Angiography of a Patient With Argus II Retinal Prosthesis One Year After Implantation.

A 58-year-old man with end-stage retinitis pigmentosa (RP) and visual acuity of light perception in both eyes received simultaneous phacoemulsification with intraocular lens implantation and implantat...

Two nematode species from freshwater and marine fishes in Thailand, including Ascarophis scatophagi sp. nov. (Cystidicolidae) from Scatophagus argus (Scatophagidae).

One new and one known species of parasitic nematodes are reported from Thailand for the first time: Falcaustra kaverii (Karve et Naik,1951) (Kathlaniidae) from the intestine of the freshwater fish Por...

Introduction.

Back cover.

Clinical Trials [16 Associated Clinical Trials listed on BioPortfolio]

New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System

This post-approval study is being implemented to monitor the use of Argus II System in a larger US population than available within pre-approval studies. An attempt will be made to includ...

Argus II Retinal Prosthesis System - Better Vision RP Study

The study is conducted to evaluate the safety and benefit of the Argus II System in a selected patient population with advanced Retinitis Pigmentosa who have a measurable central residual ...

Argus™ II Retinal Stimulation System Feasibility Protocol

The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with severe to profo...

Self-confidence Study in Patients With Argus II Artificial Retina

To evaluate whether the use of the Argus II retinal prosthesis improves the confidence and self-esteem of patients with advanced retinopathy pigmentosa

CAREN Argus Rehab (CARE) Study

The goal of the current project is to fill the unmet clinical needs around the objective assessment of visual function and develop outcome-oriented visual rehabilitation approach using the...

Companies [365 Associated Companies listed on BioPortfolio]

Argus Biosciences LLC

Argus Biosciences was founded in 2003 by Dr. David Whyte.Dr. Whyte received his Ph.D. in Molecular Biology from the University of California, San Francisco, and has a Bachelors of Science degree in Ch...

Argus Dental Plan

Founded in 2007 by a Florida dentist, Argus Dental Plan provides dental benefits that offer value and quality to all members. Argus is licensed through the Florida Department of I...

Argus Health Systems, Inc.

Argus is the leading independent provider of health care information management services supporting commercial, Medicare Part D, and Medicaid through a fully transparent business model. Argus is a who...

Argus Media

Argus is a leading provider of price assessments, business intelligence and market data on the global crude and products, natural gas, coal, electricity, emissions and transportation industries. It is...

Argus Dental & Vision, Inc.

Founded in 2007 by a Florida dentist, Argus Dental & Vision provides dental and vision benefits that offer value and quality to members. Argus is licensed through the Florida Depa...

More Information about "Argus Biosciences LLC" on BioPortfolio

We have published hundreds of Argus Biosciences LLC news stories on BioPortfolio along with dozens of Argus Biosciences LLC Clinical Trials and PubMed Articles about Argus Biosciences LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Argus Biosciences LLC Companies in our database. You can also find out about relevant Argus Biosciences LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Corporate Database Quicklinks



Searches Linking to this Company Record